Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type TumorsKurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
The Lancet. Oncology|March 19, 2017
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trialHope S Rugo, Lasika Seneviratne, J Thaddeus Beck, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
The Oncologist|March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA TrialSara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2013
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancerJ Q Chen, Y Bao, J Lee, et al.
Breast Cancer Research and Treatment|March 7, 2012
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body massHenry M Kuerer, Sara A Lari, Banu K Arun, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.
Clinical Breast Cancer|August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution ExperienceRashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type TumorsKurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Investigational New Drugs|September 28, 2020
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancerClinton Yam, Gaiane M Rauch, Tanbin Rahman, et al.
The Lancet. Oncology|March 19, 2017
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trialHope S Rugo, Lasika Seneviratne, J Thaddeus Beck, et al.
The Oncologist|August 25, 2018
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast CancerReva K Basho, Clinton Yam, Michael Gilcrease, et al.
The Oncologist|March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA TrialSara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2013
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancerJ Q Chen, Y Bao, J Lee, et al.
Breast Cancer Research and Treatment|March 7, 2012
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body massHenry M Kuerer, Sara A Lari, Banu K Arun, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.
Clinical Breast Cancer|August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution ExperienceRashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
Pageof 16